AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -76.29% | 96.34% | 788.18% | 37.62% | 133.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.29% | 96.34% | 788.18% | 37.62% | 133.29% |
| Cost of Revenue | 17.27% | 9.80% | 8.72% | 34.32% | -4.19% |
| Gross Profit | -89.51% | -0.22% | 87.23% | -33.69% | 34.15% |
| SG&A Expenses | -37.01% | -35.32% | -10.15% | 12.01% | -5.75% |
| Depreciation & Amortization | 27.79% | 28.27% | 131.51% | -85.79% | -85.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.24% | -1.59% | 60.32% | -14.91% | -33.85% |
| Operating Income | -26.60% | 8.20% | 29.87% | 18.56% | 46.94% |
| Income Before Tax | -62.24% | 6.51% | 58.36% | -9.80% | 24.58% |
| Income Tax Expenses | -118.80% | 13.46% | 16.36% | -1.08% | 85.64% |
| Earnings from Continuing Operations | -59.61% | 5.38% | 73.85% | -11.76% | 5.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.61% | 5.38% | 73.85% | -11.76% | 5.97% |
| EBIT | -26.60% | 8.20% | 29.87% | 18.56% | 46.94% |
| EBITDA | -26.46% | 11.60% | 13.76% | -25.18% | 22.51% |
| EPS Basic | -55.98% | 7.05% | 74.27% | -10.27% | 7.33% |
| Normalized Basic EPS | -58.48% | 8.09% | 34.10% | 14.25% | 25.68% |
| EPS Diluted | -51.17% | 7.05% | 73.75% | -10.27% | 7.69% |
| Normalized Diluted EPS | -58.48% | 8.09% | 34.10% | 14.25% | 25.68% |
| Average Basic Shares Outstanding | 2.36% | 1.81% | 1.43% | 1.36% | 1.46% |
| Average Diluted Shares Outstanding | 2.36% | 1.81% | 1.43% | 1.36% | 1.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |